Collins Helen Louise
Kura Oncology, Inc. · Director
Collins Helen Louise is listed in filings as Director at Kura Oncology, Inc.. This profile follows SEC Form 4 activity through Jun 4, 2026, including sale activity. Recent filings connect the profile to Kura Oncology, Inc. (KURA), Enliven Therapeutics, Inc. (ELVN), and IO Biotech, Inc. (IOBT). The current snapshot covers public activity from Oct 22, 2024 to Jun 4, 2026. Reported amounts are shown as $306.9K to $52.4K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $117k2.4k shares | SellApr 17, 2026 | $48.06 | $53.20 | |
| $115k2.4k shares | SellApr 17, 2026 | $47.39 | $53.20 | |
| $6.4k140 shares | SellApr 17, 2026 | $45.81 | $53.20 | |
| $1M40k shares | SellMar 25, 2026 | $35.10 | $53.20 | |
| $139k5k shares | SellMar 17, 2026 | $27.76 | $53.20 | |
| $306k10.1k shares | SellMar 10, 2026 | $30.19 | $53.20 | |
| $897k29.9k shares | SellMar 9, 2026 | $30.02 | $53.20 | |
| $1M45k shares | SellFeb 17, 2026 | $26.17 | $53.20 | |
| $24k816 shares | SellOct 18, 2024 | $30.00 | $53.20 |